Recruiting Alzheimers Disease Studies in Riverside
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies....
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo....
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
The main purpose of the study is to evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with nivolumab in participants with high risk MIUC. In this study parti...
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety...
About Alzheimers Disease Clinical Trials in Riverside
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 4 alzheimers disease clinical trials recruiting participants in Riverside, CA. These studies are seeking a combined 14,168 participants. Research is being sponsored by Hoffmann-La Roche, Janssen Pharmaceutica N.V., Belgium, Otsuka Pharmaceutical Development & Commercialization, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in Riverside — FAQ
Are there alzheimers disease clinical trials in Riverside?
Yes, there are 4 alzheimers disease clinical trials currently recruiting in Riverside, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Riverside?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Riverside research site will contact you about next steps.
Are clinical trials in Riverside free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Riverside studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 4 active trials in Riverside are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov